Toxicities of Antibody–Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management
Luisana Sisca, Mariam Grazia Polito, Arianna Travisani, Fernando Zannino, Michele Iuliani, Giuseppe Tonini, Francesco Pantano · 2026
Read Toxicities of Antibody–Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management by Luisana Sisca, Mariam Grazia Polito, Arianna Travisani, Fernando Zannino, Michele Iuliani, Giuseppe Tonini, Francesco Pantano (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13416289.txt.
Description
Luisana Sisca and colleagues review the side effects of antibody drug conjugates in breast cancer, in 2026. These drugs pair a targeting antibody with a toxic payload, and their use has transformed breast cancer care. Harm patterns extend beyond classic chemotherapy effects, spanning blood, lung, gut, liver, nerve, mouth, eye, skin, and heart.
Toxicity depends on payload class, linker stability, target biology, and how much payload leaks into general circulation. Patient traits add further variation. Several harms can be anticipated with monitoring and early action, yet validated predictive biomarkers are largely missing. Care should be individualized and multidisciplinary, the authors argue.
Catalog record
| CREATOR | Luisana Sisca, Mariam Grazia Polito, Arianna Travisani, Fernando Zannino, Michele Iuliani, Giuseppe Tonini, Francesco Pantano |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63196 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |